Jubilant Pharmova names Arun Kumar Sharma as interim CFO

Published On 2025-09-23 11:23 GMT   |   Update On 2025-09-23 11:23 GMT
Advertisement

Noida: Jubilant Pharmova has announced the appointment of Arun Kumar Sharma as a Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from October 1, 2025.

He shall hold the CFO office for an interim period till the appointment of new CFO.

"we wish to inform that the Board of Directors of the Company, at its meeting held on September 23, 2025, on the recommendation of Nomination, Remuneration and Compensation Committee and the Audit Committee, had considered and approved the appointment of Mr. Arun Kumar Sharma as a Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from October 1, 2025," the company stated in a BSE filing.

Advertisement

"The appointment is made for an interim period to ensure a smooth transition to the new Chief Financial Officer, for which the identification and appointment process is in progress," it added.

Arun Kumar Sharma is a strategic and result-driven financial company with over three decades of progressive experience across corporate finance, global treasury, investor relations, risk management, financial restructuring, insurance, capex control, and business transformation.
He has consistently demonstrated excellence in driving sustainable growth, enhancing shareholder value, and upholding governance standards in large listed companies. He has held various positions in Jubilant Bhartia Group including CFO role in Jubilant Pharma Holdings Inc. USA for approx. 4 years, Jubilant Lifesciences Limited (Chemical Business) for approx. 3 years and Jubilant Pharmova Limited for approx. 2 years (April’ 2021-May’2023).

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News